Paromomycin sulfate

From Wikipedia, the free encyclopedia

Paromomycin sulfate
Systematic (IUPAC) name
(2R,3S,4R,5R,6S)-5-amino-6-[(1R,2S,3S,4R,6S)- 4,6-diamino-2-[(2S,3R,4R,5R)-4-[(2R,3R,4R,5R,6S)- 3-amino-6-(aminomethyl)-4,5-dihydroxy-oxan-2-yl] oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy- 3-hydroxy-cyclohexyl]oxy-2-(hydroxymethyl)oxane-3,4-diol
Identifiers
CAS number	1263-89-4
ATC code	?
PubChem	165580
DrugBank	?
Chemical data
Formula	C23H47N5O18S
Mol. mass	615.629 g/mol
Pharmacokinetic data
Bioavailability	None
Metabolism	None
Half life	?
Excretion	Fecal
Therapeutic considerations
Pregnancy cat.	C(US)
Legal status	Schedule VI U.S.
Routes	Oral, intramuscular

Paromomycin sulfate (brand name Humatin®) is a drug that fights intestinal infections such as cryptosporidiosis and amoeba infection, or amoebiasis and was developed as a therapeutic against visceral leishmaniasis by the Institute for OneWorld Health. Paromomycin was granted orphan drug status in 2005^[1] and was approved by the Drug Controller General of India in September 2006 for treatment visceral leishmaniasis.^[2]

Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA.^[3]

[edit] References

1. ^ Institute for OneWorld Health (23 May 2005). Institute for OneWorld Health Drug Receives “Orphan” Designation From U.S. and European Regulatory Agencies. Press release. Retrieved on 2007-02-10.
2. ^ Institute for OneWorld Health (8 September 2006). New cure for deadly visceral leishmaniasis (kala-azar) approved by government of India. Press release. Retrieved on 2007-02-10.
3. ^ Vicens, Quentin; Eric Westhof (August 2001). "Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A Site". Structure 9 (8): 647–658. DOI:10.1016/S0969-2126(01)00629-3. PMID 11587639. Retrieved on 2007-02-10.